![Medtronic PROTECTA XT DR D314DRG Скачать руководство пользователя страница 356](http://html.mh-extra.com/html/medtronic/protecta-xt-dr-d314drg/protecta-xt-dr-d314drg_clinician-manual_1763148356.webp)
9 Configuring tachyarrhythmia therapies
9.1 Treating episodes detected as VF
Ventricular fibrillation (VF) is recognized by the presence of a grossly irregular ventricular
rhythm. VF is life threatening if it is not treated promptly with defibrillation therapy.
9.1.1 System solution: VF therapies
The device can respond to ventricular tachyarrhythmia episodes detected in the VF zone
(VF episodes) by delivering defibrillation therapy to the patient’s heart. The defibrillation
therapy is intended to terminate the episode by simultaneously depolarizing the heart tissue
and restoring the patient’s normal sinus rhythm.
The device can be programmed to deliver a sequence of ventricular antitachycardia pacing
(ATP) therapy before or during charging for the first defibrillation therapy. This allows the
device to attempt to terminate rapid but stable ventricular tachyarrhythmias that may not
require defibrillation therapy for termination.
For related information, refer to Section 8.2, “Detecting ventricular tachyarrhythmias”,
page 304, and to Section 9.2, “Treating VT and FVT episodes with antitachycardia pacing
9.1.2 Operation of VF therapies
The device can be programmed to deliver a sequence of up to 6 therapies to treat VF
episodes, each with specific energy and pathway settings. If the first therapy (labeled Rx1)
is successful in terminating the episode, the device continues monitoring for subsequent
VF episodes. If the device redetects the VF episode after the first therapy delivery, it delivers
the second VF therapy (labeled Rx2). If the second therapy is successful, the device
continues monitoring for subsequent VF episodes. It continues this process until either the
episode terminates or the last programmed therapy has been delivered.
For the first VF therapy (Rx1), the device can be programmed to attempt to terminate the
ventricular tachyarrhythmia with ventricular antitachycardia pacing (ATP) therapy before
delivering a defibrillation shock. This may allow the device to terminate rapid but stable
ventricular tachyarrhythmias that do not require defibrillation therapy. ATP therapy can be
programmed to deliver before or during charging for the first defibrillation therapy.
During charging for Rx1, the device attempts to confirm the continued presence of VF before
delivering the shock. If the VF has stopped spontaneously or if it has been terminated by
ATP During Charging, the device cancels the therapy and resumes monitoring.
Medtronic
PROTECTA™ XT DR D314DRG
356
Clinician Manual
Содержание PROTECTA XT DR D314DRG
Страница 2: ......
Страница 9: ...Index 488 Medtronic PROTECTA XT DR D314DRG Clinician Manual 9 ...
Страница 506: ......
Страница 507: ......